Interchemie

Veterinary medicines for the world

• Fund V
• VETERINARY MEDICINES
• Entry 2025
• Exit -
• Sales €90 million

New partnership between Interchemie and investment company Nimbus. In April 2025, Nimbus signed a partnership with Maco Investments and acquired a majority stake in Interchemie and its affiliated local entities in Estonia and Lithuania.

Interchemie is active since 1979 in the veterinary medicine segment and has become a leading player in the animal health sector. The company develops, produces and offers a broad range of veterinary medicines, nutritional products and disinfectants, primarily for livestock. Interchemie is active on a global scale and sells its products through c. 135 distributors all around the world. In close cooperation with the management team, Nimbus aims to further build and strengthen Interchemie's leading position in Africa and the Middle East and achieve further expansion in Asia and (Western) Europe.

In September 2025, Interchemie, Kepro and Pharmapark decided to join forces to create a powerful combination. By combining the strengths in marketing, sales, and manufacturing of world-class veterinary medicines, customers can be offered more choice, excellent quality and service, while securing production capacity and compliance. In doing so, the combination aims to achieve a world-leading position in generic veterinary pharmacy.

Bernard Verburg (CEO) looks to the future with great confidence:

"We are delighted with the cooperation with Nimbus, Kepro and Pharmapark. Thanks to the great commitment and dedication of the fantastic teams at both Interchemie and Kepro and Pharmapark, we can further expand our leading market position. The partnership with all these stakeholders offers the opportunity to further strengthen the combined business of Interchemie, Kepro and Pharmapark in the next phase of development and work together to make the company even more successful."